BUSINESS
Pharmacy strike: Medical stores cite job loss, drug abuse as risks from online sales
Union health ministry earlier this month notified rules that would allow online pharmacies to register and dispense all medicines
BUSINESS
Ayushman Bharat gets a boost as SC makes Aadhaar mandatory
"We would prefer to have Aadhaar, however will not deny services if there is no Aadhaar," said Indu Bhushan, Chief Executive Officer (CEO) of Pradhan Mantri Jan Arogya Yojana (PM-JAY) and NHA to Moneycontrol.
BUSINESS
Alcon sees huge potential in Indian eye care segment led by surge in cataract surgeries
India is home to around 30 percent of the world’s blind people, about half of whom are blind from cataracts.
BUSINESS
Will Modicare be a game changer or turn into another Rashtriya Swasthya Bima Yojana?
The scheme aims to provide Rs 5 lakh coverage to 100 million poor vulnerable families translating into 500 million individual beneficiaries, which is more than the population of North America
BUSINESS
The curious case of missing patients with J&J's ASR hip implant
J&J had earlier informed CDSCO that around 93,000 people worldwide had ASR implanted. And of the 4,700 ASR surgeries performed in India, just 882 patients could be traced
BUSINESS
Exclusive | Fully prepared for rollout with 31 states, 9,000 private hospitals on board: Ayushman Bharat CEO
"We are fully prepared, it's a big scheme, there is no start or end point, it's a continuum," said Indu Bhushan, CEO of Pradhan Mantri Jan Arogya Yojana and NHA
BUSINESS
Biocon closer to Europe approval of biosimilar pegfilgrastim
Amgen's Neulasta had brand sales of more than $450 million in Europe for the 12 months ending June 30, 2018, according to market research firm IQVIA.
BUSINESS
Exclusive | How Lupin plans to counter dwindling sales growth in Japan
Even as the company faces another price cut in Japan, Lupin looks to rationalise costs, shift manufacturing units and looks at non-Japanese markets to continue growth
BUSINESS
Fortis gets first credit rating upgrade in a long time on Rs 450 crore loan
The rating upgrade of Fortis is for Rs 250 crore non-convertible debentures, Rs 105 crore fund-based limits and term loan of Rs 105 crore.
BUSINESS
NYSE-listed Rockwell helps Indian drug makers automate factories to raise quality, cut costs
"If you are a pharma CEO, what keeps you up at night, is the regulator," says Rockwell India Managing Director Dilip Sawhney
BUSINESS
Expert panel says firms failed to submit coherent data on safety, efficacy of fixed dose drugs
The report said the published literature provided by drug companies to justify their FDCs were not relevant and relied on a few biased studies
BUSINESS
Can Alok Sonig bring the mojo back to Lupin's US generics business?
The company said Sonig will lead and have overall responsibility for the US generics business including Research & Development in India and the US and the Commercial side of the business in the US.
BUSINESS
Meet S Srinivasan, the activist-entrepreneur who got 329 irrational combination drugs banned
Srinivasan and his team at AIDAN have been working to bring curtains down on hundreds of irrational fixed drug combinations that have no scientific basis.
BUSINESS
Patients of J&J's faulty hip implant demand seat on expert panel to fix compensation
The demand comes at a time when the Central committee, being set up for compensation, is likely to meet for the first time on September 18.
BUSINESS
Pharma weekly wrap: FDC ban and Shivinder Singh's U-turn hog the limelight
The government ban on FDCs mostly covered drug cocktails for treating cold and cough, antibiotics, painkillers, anti-depressants, diabetic drugs, among others.
BUSINESS
Split with brother stands, but Shivinder looks to bury the hatchet via mediation
Shivinder further added that in case the mediation falls through, he intends to reassess and start a fresh action against his brother
BUSINESS
Shivinder Mohan Singh withdraws NCLT petition against elder brother Malvinder Singh
Shivinder had earlier on September 4 filed a case against Malvinder and Sunil Godhwani in the NCLT, alleging 'oppression and mismanagement' of RHC Holding, Religare Enterprises and Fortis Healthcare.
BUSINESS
PM Narendra Modi's push for generic drugs is benefiting this upcoming pharmacy retail chain
The self-funded startup has managed to sign up 88 retail generic stores on franchisee model in the last 100 days and plans to open one store every 48 hours
BUSINESS
Garden Reach Shipbuilders to focus on repairs & lowering material costs to boost margin
The Kolkata-based shipbuilder that builds warships and patrol vessels for Indian Navy and Coast Guard will be launching its IPO on September 24 at price band of Rs 115- 118 per equity share
BUSINESS
Indian pharma market grew 8.7% in August on slower offtake of anti-infectives
IPM grew close to 10 percent in first five months of this financial year FY19, returning to the 10 percent growth of FY17.
BUSINESS
Tata Power plans big play in nascent rooftop solar power generation market
Tata Power management considers renewables as one of the key growth focus areas and is targeting 40-50 percent of its total generation capacity from non-fossil fuel based generation sources by 2025.
BUSINESS
Actavis to Sandoz, Aurobindo Pharma is scaling up biz one acquisition at a time
Aurobindo’s past record of integrating and turning around acquired companies is what keeps investors excited about.
BUSINESS
Abbott gets reprieve from Supreme Court in FDC ban case
The court directed the Central government to exclude 15 fixed dose combination (FDC) medications from the ban recommended by a sub-committee appointed by Drugs Technical Advisory Board.
BUSINESS
Pharma weekly wrap: A busy week with Aurobindo's US buyout and break-up of Singh brothers
The cheaper valuation of the acquisition target and Aurobindo's past track record in integrating and turning around acquired companies made most analysts and investors give was thumbs-up to the deal
